Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02034357 · ClinicalTrials.gov registry record · NA

Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease

A NA study, sponsored by University of Miami.

Completed
Registry status
NA
Development phase
89
Enrollment target

NCT02034357: Completed NA study, sponsored by University of Miami.

NCT02034357 is a NA study that has completed, run by University of Miami. The registered enrollment target is 89 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02034357, a NA study, has completed, sponsored by University of Miami.

COMPLETED
Registry status
NA
Development phase
89 participants
Enrollment target

Study Summary

The purpose of this study is to determine the impact of sleep and breathing problems during sleep on memory, attention, and general well being (quality of life) in people with Parkinson Disease.

Primary Outcome

Changes from Baseline Neurocognitive function (verbal learning and memory) in Parkinson's disease patients at 4 month and 1 year follow-up as measured by California Verbal Learning Test (CVLT).

Interventions

  • OTHER Neurocognitive function
  • OTHER Sleep evaluations

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 2011-06
Est. Completion 2016-03
Phase NA
University of Miami

721 total trials

What the finished NCT02034357 record still lists

NCT02034357 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 2 interventions - of which Neurocognitive function is the first listed.

NCT02034357 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02034357 about?

NCT02034357 is a clinical study titled "Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease". The purpose of this study is to determine the impact of sleep and breathing problems during sleep on memory, attention, and general well being (quality of life) in people with Parkinson Disease.

What is the current status of trial NCT02034357?

This trial is currently completed. It is a NA study. The enrollment target is 89 participants. The study started on 2011-06. Estimated completion is 2016-03.

What interventions are being tested in trial NCT02034357?

The interventions under investigation include: Neurocognitive function (OTHER), Sleep evaluations (OTHER).

Who is sponsoring clinical trial NCT02034357?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02034357's enrollment target sits among peer trials

89 972nd of 2000 higher than 1,029 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03682289 · 89 participants · Phase 2

    Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

  • NCT04787939 · 89 participants · NA

    Early Feeding After Oral Cavity Reconstruction

  • NCT05480449 · 89 participants · Phase 1

    Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

  • NCT05604131 · 89 participants · Phase 2

    Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02034357, the US trial registry maintained by the National Library of Medicine. NCT02034357 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.